Magle Chemoswed Holding AB (MAGLE) AI Stock Analysis

• Market Cap: kr86.73M
• Dividend Yield: N/A
• Average Volume (3M): 1.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.41
• Revenue Growth: 41.83%
• EPS Growth: -183.68%
• Country: SE
• Employees: 147
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -6.49
• Shares Outstanding: 20,649,378
• 10 Day Avg. Volume: 1,291
• 30 Day Avg. Volume: 1,058
• PEG Ratio: <0.01
• Price to Book (P/B): 0.92
• Price to Sales (P/S): 1.28
• P/FCF Ratio: -11.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.4
• Revenue Forecast (FY): kr377.00M

• Rating: 40 Underperform
• Price Target: kr4.00 ▼(-76.74% Downside)
• Action: Downgraded Date: 04/02/26
• Date: Action: Downgraded 04/02/26

The score is primarily held back by deteriorating financial performance (2025 losses and two consecutive years of negative operating/free cash flow) and strongly bearish technicals (price far below key moving averages with negative MACD and very weak RSI/Stoch). Valuation provides limited offset given the elevated P/E and no dividend yield data.

Positive Factors

Business model & industry exposure

Magle’s core business—contract development (formulation/process) and manufacturing—creates recurring project and manufacturing revenue streams tied to pharmaceutical development cycles. This service-oriented model provides durable demand from drug sponsors and helps diversify revenue across projects and customers over the medium term.

Negative Factors

Two-year negative cash generation

Sustained negative operating and free cash flow over the last two years materially increases funding dependence and limits internal financing for capex, R&D, or working capital. Over a 2–6 month horizon this structural cash weakness raises refinancing risk and constrains strategic flexibility if losses continue.

Magle Chemoswed Holding AB Business Overview & Revenue Model

Company Description

Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacturing in the areas of pharmaceutical chemistry and pharmaceutical technology in Sweden. The company focuses on the process development and manufacture of active ph...

Read more

Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacturing in the areas of pharmaceutical chemistry and pharmaceutical technology in Sweden. The company focuses on the process development and manufacture of active ph...

How the Company Makes Money

Magle Chemoswed Holding AB (MAGLE) makes money primarily by providing services and products within pharmaceutical development and manufacturing. Key revenue streams include (1) contract development work (e.g., formulation/process development and r...

Read more

Magle Chemoswed Holding AB (MAGLE) makes money primarily by providing services and products within pharmaceutical development and manufacturing. Key revenue streams include (1) contract development work (e.g., formulation/process development and r...

Magle Chemoswed Holding AB Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	282.92M	236.04M	170.44M	145.68M	132.15M
Gross Profit	232.43M	221.55M	152.87M	134.38M	110.83M
EBITDA	-24.25M	59.21M	31.40M	25.77M	18.14M
Net Income	-159.88M	11.94M	12.17M	9.14M	4.28M
Balance Sheet
Total Assets	911.03M	1.09B	272.97M	252.86M	237.18M
Cash, Cash Equivalents and Short-Term Investments	13.59M	2.72M	7.08M	9.88M	3.98M
Total Debt	346.19M	359.92M	60.30M	50.34M	36.46M
Total Liabilities	515.19M	531.58M	114.75M	106.09M	98.39M
Stockholders Equity	395.84M	560.60M	158.22M	146.77M	138.79M
Cash Flow
Free Cash Flow	-31.93M	-27.85M	209.00K	-4.41M	14.21M
Operating Cash Flow	-31.93M	-11.70M	15.33M	12.47M	26.04M
Investing Cash Flow	-12.59M	-9.97M	-20.41M	-21.49M	-34.05M
Financing Cash Flow	55.45M	17.09M	2.52M	14.80M	5.87M

Magle Chemoswed Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 17.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MAGLE, the sentiment is Negative. The current price of 17.2 is above the 20-day moving average (MA) of 6.64, above the 50-day MA of 8.77, and below the 200-day MA of 17.57, indicating a bearish trend. The MACD of -1.40 indicates Positive momentum. The RSI at 20.82 is Positive, neither overbought nor oversold. The STOCH value of 5.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MAGLE.

Magle Chemoswed Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IVACC	52 Neutral	kr293.10M	-3.40	-25.80%	―	127.13%	56.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XBRANE	46 Neutral	kr144.03M	121.99	-16.90%	―	4.64%	―
CLBIO	46 Neutral	kr420.06M	-27.57	―	―	―	―
IMMU	45 Neutral	kr271.88M	-1.89	-16.51%	―	―	31.37%
GUARD	42 Neutral	kr27.43M	-0.24	-186.13%	―	―	0.30%
MAGLE	40 Underperform	kr86.73M	-2.27	-4.90%	―	41.83%	-183.68%